A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Prior treatment

• General Exclusion Criteria - History of hypersensitivity, a severe allergic reaction or anaphylactic reaction to any component of the investigational drug injection
• Current or prior history of central serous retinopathy
• Current or prior history of choroidal neovascularization (CNV) in either eye

Other illness

• History of diabetic macular edema (DME), retinal vein occlusion, corneal transplant, retinal detachment, Stage 3 or 4 macular hole, optic neuropathy, or retinal dystrophy
• History of recurrent infectious or inflammatory ocular disease

Other

• Ocular Exclusion Criteria for the Study Eye
• Aphakia or absence of the posterior capsule in the study eye
  • Ocular Exclusion Criteria for the Non-Study Eye
  • \- Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of non-study eye (i.e., monocular)
  • Ocular Exclusion Criteria for Either Eye
• Proliferative diabetic retinopathy
• Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Other protocol-defined inclusion/exclusion criteria may apply

• Ocular Inclusion Criteria for the Study Eye
• BCVA score of \>= 35 letters using the ETDRS VA chart at a starting distance of 4 meters
• Lesions may be either extrafoveal or subfoveal
  • Ocular Inclusion Criteria for Both Eyes
• Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
• Well-demarcated GA secondary to AMD